Genome-wide association studies: Inherent limitations and future challenges

被引:25
作者
Yan Du
Jiaxin Xie
Wenjun Chang
Yifang Han
Guangwen Cao
机构
[1] Department of Epidemiology, Second Military Medical University, Shanghai
基金
中国国家自然科学基金;
关键词
cancer; challenge; genetic variant; genome-wide association studies (GWAS); limitation;
D O I
10.1007/s11684-012-0225-3
中图分类号
学科分类号
摘要
Genome-wide association studies (GWAS) have achieved great success in identifying genetic variants related to complex human diseases such as cancer and have provided valuable insights into their genetic architecture. Recently, GWAS is quite the fashion in China. However, there are issues related to its nature. Enormous work needs to be done in the post-GWAS era. Deep sequencing followed by functional studies will be needed to elucidate the underpinning biological mechanisms and further translate GWAS findings into medical practice. Along with pharmacogenomics, the success of GWAS in identifying genetic risk factors and genetic differences in drug response has been gradually enabling personalized medicine. In this article, we used hepatocellular carcinoma (HCC) as an example to demonstrate some of the inherent limitations and summarized future challenges of GWAS. © 2012 Higher Education Press and Springer-Verlag Berlin Heidelberg.
引用
收藏
页码:444 / 450
页数:6
相关论文
共 33 条
[11]  
Nat Genet, 43, 7, (2011)
[12]  
Amos C.I., Wu X., Broderick P., Gorlov I.P., Gu J., Eisen T., Dong Q., Zhang Q., Gu X., Vijayakrishnan J., Sullivan K., Matakidou A., Wang Y., Mills G., Doheny K., Tsai Y.Y., Chen W.V., Shete S., Spitz M.R., Houlston R.S., Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1, Nat Genet, 40, 5, pp. 616-622, (2008)
[13]  
Hung R.J., McKay J.D., Gaborieau V., Boffetta P., Hashibe M., Zaridze D., Mukeria A., Szeszenia-Dabrowska N., Lissowska J., Rudnai P., Fabianova E., Mates D., Bencko V., Foretova L., Janout V., Chen C., Goodman G., Field J.K., Liloglou T., Xinarianos G., Cassidy A., McLaughlin J., Liu G., Narod S., Krokan H.E., Skorpen F., Elvestad M.B., Hveem K., Vatten L., Linseisen J., Clavel-Chapelon F., Vineis P., Bueno-De-Mesquita H.B., Lund E., Martinez C., Bingham S., Rasmuson T., Hainaut P., Riboli E.,
[14]  
Chung C.C., Chanock S.J., Current status of genome-wide association studies in cancer, Hum Genet, 130, 1, pp. 59-78, (2011)
[15]  
Manolio T.A., Collins F.S., Cox N.J., Goldstein D.B., Hindorff L.A., Hunter D.J., McCarthy M.I., Ramos E.M., Cardon L.R., Chakravarti A., Cho J.H., Guttmacher A.E., Kong A., Kruglyak L., Mardis E., Rotimi C.N., Slatkin M., Valle D., Whittemore A.S., Boehnke M., Clark A.G., Eichler E.E., Gibson G., Haines J.L., Mackay T.F., McCarroll S.A., Visscher P.M., Finding the missing heritability of complex diseases, Nature, 461, 7265, pp. 747-753, (2009)
[16]  
Lango Allen H., Estrada K., Lettre G., Berndt S.I., Weedon M.N., Rivadeneira F., Willer C.J., Jackson A.U., Vedantam S., Raychaudhuri S., Ferreira T., Wood A.R., Weyant R.J., Segre A.V., Speliotes E.K., Wheeler E., Soranzo N., Park J.H., Yang J., Gudbjartsson D., Heard-Costa N.L., Randall J.C., Qi L., Vernon Smith A., Magi R., Pastinen T., Liang L., Heid I.M., Luan J., Thorleifsson G., Winkler T.W., Goddard M.E., Sin Lo K., Palmer C., Workalemahu T., Aulchenko Y.S., Johansson A., Zillikens M.C.
[17]  
Miki D., Ochi H., Hayes C.N., Aikata H., Chayama K., Hepatocellular carcinoma: towards personalized medicine, Cancer Sci, 103, 5, pp. 846-850, (2012)
[18]  
Aravalli R.N., Steer C.J., Cressman E.N., Molecular mechanisms of hepatocellular carcinoma, Hepatology, 48, 6, pp. 2047-2063, (2008)
[19]  
Han Y.F., Zhao J., Ma L.Y., Yin J.H., Chang W.J., Zhang H.W., Cao G.W., Factors predicting occurrence and prognosis of hepatitis-B-virusrelated hepatocellular carcinoma, World J Gastroenterol, 17, 38, pp. 4258-4270, (2011)
[20]  
Nguyen V.T., Law M.G., Dore G.J., Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden, J Viral Hepat, 16, 7, pp. 453-463, (2009)